Rosiglitazone induced neuronal mitochondrial biogenesis and improved glucose utilization in mice in an apolipoprotein E-independent manner leading to improved cellular function and providing further evidence for PPARγ as a therapeutic target in AD [81]. This evidence concerns the gene PPARG and Alzheimer disease.